“Retinal Crystals In Type 2 Idiopathic Macular Telangiectasia.”. Ophthalmology 118 (12). Ophthalmology: 2461-7. doi:10.1016/j.ophtha.2011.05.022.
. 2011. “Agreement Between Time-Domain And Spectral-Domain Optical Coherence Tomography In The Assessment Of Macular Thickness In Patients With Idiopathic Macular Telangiectasia Type 2.”. Ophthalmologica 230 (3). Ophthalmologica: 144-50. doi:10.1159/000353455.
. 2013. “Is Indocyanine Green Angiography Useful For The Diagnosis Of Macular Telangiectasia Type 2?”. Br J Ophthalmol 97 (7). Br J Ophthalmol: 946-8. doi:10.1136/bjophthalmol-2013-303118.
. 2013. “Associations Between Autofluorescence Abnormalities And Visual Acuity In Idiopathic Macular Telangiectasia Type 2: Mactel Project Report Number 5.”. Retina 34 (8). Retina: 1630-6. doi:10.1097/IAE.0000000000000110.
. 2014. “Multimodal Imaging In Type 2 Idiopathic Macular Telangiectasia.”. Retina 35 (4). Retina: 742-9. doi:10.1097/IAE.0000000000000365.
. 2015. “Abnormal Retinal Reflectivity To Short-Wavelength Light In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S79-S88. doi:10.1097/IAE.0000000000001728.
. 2018. “Characteristics Of Pigmented Lesions In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S43-S50. doi:10.1097/IAE.0000000000001842.
. 2018. “Correlation Of Clinical And Structural Progression With Visual Acuity Loss In Macular Telangiectasia Type 2: Mactel Project Report No. 6-The Mactel Research Group.”. Retina 38 Suppl 1. Retina: S8-S13. doi:10.1097/IAE.0000000000001697.
. 2018. “Correlation Of Structural And Functional Outcome Measures In A Phase One Trial Of Ciliary Neurotrophic Factor In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S27-S32. doi:10.1097/IAE.0000000000001706.
. 2018. “Potential Effects Of Hormone Therapy In Type 2 Idiopathic Macular Telangiectasia.”. Ophthalmic Res 60 (1). Ophthalmic Res: 38-42. doi:10.1159/000479932.
. 2018.